<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217568</url>
  </required_header>
  <id_info>
    <org_study_id>PSOC 1702</org_study_id>
    <secondary_id>PSOC-1702</secondary_id>
    <secondary_id>AVENTIS-PSOC-1702</secondary_id>
    <secondary_id>PSOC-IRB-4861</secondary_id>
    <secondary_id>CDR0000441307</secondary_id>
    <nct_id>NCT00217568</nct_id>
  </id_info>
  <brief_title>Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer</brief_title>
  <official_title>A Phase II Trial of Docetaxel and Carboplatin for First Relapsed Platinum-Sensitive Stage III and IV Advanced Ovarian Cancer or Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving docetaxel together with carboplatin&#xD;
      works in treating patients with relapsed stage III or stage IV ovarian epithelial or primary&#xD;
      peritoneal cavity cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity of docetaxel and carboplatin in patients with platinum-sensitive&#xD;
           stage III or IV ovarian epithelial or primary peritoneal cavity cancer in first relapse.&#xD;
&#xD;
        -  Determine the response rates (complete and partial response) in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine relapse rates and event-free survival and overall survival rates in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1.&#xD;
      Patients also receive pegfilgrastim subcutaneously on day 2 . Treatment repeats every 21 days&#xD;
      for up to 6 courses.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 weeks, every 3 months for 2&#xD;
      years, and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 4-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rates (complete and partial response)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse rates</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial or primary peritoneal cavity cancer&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
               -  No borderline tumors&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease, defined as evidence of disease by physical examination or&#xD;
                  radiographic evaluation&#xD;
&#xD;
               -  Evaluable disease, defined as CA 125 ≥ 100 U/mL (confirmed by 2 blood tests&#xD;
                  performed ≥ 1 week apart)&#xD;
&#xD;
          -  In first relapse&#xD;
&#xD;
               -  Platinum-sensitive disease, defined as initial relapse &gt; 6 months after&#xD;
                  completion of a platinum-based regimen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  SGOT and/or SGPT ≤ 1.5 times upper limit of normal (ULN) AND alkaline phosphatase&#xD;
                  (AP) ≤ 2.5 times ULN&#xD;
&#xD;
               -  SGOT and/or SGPT ≤ 5.0 times ULN AND AP normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  No poorly controlled arrhythmia&#xD;
&#xD;
          -  No unstable coronary artery disease or myocardial infarction within the past year&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy &gt; grade 2&#xD;
&#xD;
          -  No history of allergy to study drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from recent prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent myelosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona A. Holmberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Gynecology Specialists</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

